Analysts Anticipate TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million
Wall Street analysts expect that TESARO, Inc. (NASDAQ:TSRO) will post sales of $17.22 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for TESARO’s earnings, with estimates ranging from $10.77 million to $24.67 million. TESARO posted sales of $36.56 million in the same quarter last year, which suggests a negative year-over-year growth rate of 52.9%. The business is expected to announce its next earnings results on Thursday, August 3rd.
According to Zacks, analysts expect that TESARO will report full year sales of $17.22 million for the current financial year, with estimates ranging from $67.34 million to $196.00 million. For the next financial year, analysts forecast that the company will post sales of $428.83 million per share, with estimates ranging from $231.30 million to $554.79 million. Zacks’ sales averages are an average based on a survey of research firms that follow TESARO.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The firm’s revenue for the quarter was up 909.8% on a year-over-year basis. During the same period last year, the business posted ($2.22) EPS.
TSRO has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Wednesday, March 22nd. Piper Jaffray Companies initiated coverage on shares of TESARO in a research note on Wednesday, April 12th. They set an “overweight” rating and a $180.00 price target for the company. Leerink Swann restated a “market perform” rating on shares of TESARO in a research note on Monday, March 20th. Robert W. Baird lowered shares of TESARO from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $127.00 to $182.00 in a research note on Monday, February 27th. Finally, Jefferies Group LLC boosted their price target on shares of TESARO from $80.00 to $124.00 and gave the company a “hold” rating in a research note on Monday, March 27th. Nine research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $173.68.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $153.02, for a total transaction of $126,853.58. Following the completion of the transaction, the senior vice president now owns 6,522 shares in the company, valued at $997,996.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Vident Investment Advisory LLC bought a new position in TESARO during the first quarter valued at $351,000. Meeder Asset Management Inc. bought a new position in TESARO during the first quarter valued at $177,000. Soros Fund Management LLC bought a new position in TESARO during the first quarter valued at $262,000. Stephens Inc. AR raised its position in TESARO by 11.0% in the first quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 175 shares during the last quarter. Finally, First Citizens Bank & Trust Co. bought a new position in TESARO during the first quarter valued at $288,000.
TESARO (TSRO) traded up 1.2667% on Friday, reaching $151.6671. 519,149 shares of the company were exchanged. The company’s 50-day moving average price is $145.51 and its 200-day moving average price is $151.49. TESARO has a 12-month low of $36.71 and a 12-month high of $192.94. The stock’s market capitalization is $8.17 billion.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.